Connect with us

BUSINESS

CV Sciences Inc (OTCMKTS:CVSI) Shareholders Receive A Letter From The Company

Published

on

The shareholders of CV Sciences Inc (OTCMKTS:CVSI) today received a letter from the company. It served them with details regarding the progress this business guru has made lately. Aside from that, these shareholders have also been enlightened on the company’s upcoming objectives.

Joseph Dowling, current Chief Executive Officer of CV Sciences Inc spoke elaborately regarding the company’s uplist initiative to an outstanding national exchange. The national exchanges usually operate on a set of principles. They provide that the stock of any given company trade at particular level for acceptance.

A close outlook at the matter

We are moving closer to the company’s AGM. And there is a proposal for shareholders to be included in the voting exercise that will be conducted. It will be a great opportunity for shareholders to express themselves in line with the planned reverse stock split initiative.

Most of the interested parties are looking forward to see this company up-listed. Finding a place among the major national exchanges will be a great step forward for CV Sciences Inc. It will be able to draw more investors to itself, a move deemed crucial towards attainment of further growth and expansion.

Current state of affairs

Since its establishment, this company has been running two distinct business segments. One of them is a consumer product division and the other is a drug development division. The first one focuses in the manufacture and sale of a wide range of plant-based CBD products. The second one is about the development and commercialization of top end therapeutics utilizing synthetic CBD.

This company’s Chief Executive Officer is quite pleased with growth levels achieved so far. He believes that the company’s retail channel expansion tells it all. He also made reference to the hemp CBD products of this company outlining that recently there had been increased industry forecasts.

It goes without saying that the hemp CBD product segment has been experiencing immense growth lately. A trusted source indicates that 2017 sales of this company hit the $174 million mark. It is expected that by 2021 the hemp CBD market will have reached about $1.6 billion.

BUSINESS

Blackbird Holdings Corp, A Subsidiary Of TILT Holdings Inc (OTCMKTS:TLLTF), Partners With Cova Software To Provide Retail Solution For Dispensaries And Cannabis Stores

Published

on

Blackbird Holdings Corp, a subsidiary of TILT Holdings Inc (OTCMKTS:TLLTF), decided to offer cannabis dispensaries and stores a retail solution to facilitate home delivery, point of sale (POS), online ordering, and customer retention by partnering with Cova Software. Following this deal, the company integrated the cannabis POS of Cova Software with its all-in-one retail platform for cannabis distribution and e-commerce.

Eliminates the need for double entries

Blackbird’s pact with Cova Software eliminates the need for double entries in in-store and online sales. It helps the cannabis stores and dispensaries to retain existing customers and attract new consumers.

Chief Executive Officer of Tilt, Mark Scatterday said Cova Software has a close relationship with its business since the beginning. The company is excited to extend that association and integrate the technologies of both Cova Software and Blackbird to offer a seamless and simple retail solution for the dispensaries and cannabis stores to manage sales and customers with ease.

The retailers of Cova POS can add dynamic online menu capabilities with the help of Blackbird. Customer records are created automatically in Cova when a customer creates an account and places an order. The order placed by the customer is automatically saved in the retail system of Cova.

Faster processing of customer orders

The integrated retail solution facilitates faster processing of orders and maintains up to date store inventory in real-time on the menus of Blackbird. It specifies product availability, product information, and pricing.

Chief Executive Officer of Cova Software, Gary Cohen said its team always strives to improve the shopping experience of customers through innovative ways and enhancements. Therefore, collaboration with Blackbird helps to create a rewarding experience for the customers across all the touchpoints and provide a simplified retail solution to the retailers. It eliminates the complexity of running a cannabis store or dispensary and ensures efficient operation.

The users of Cova will also enjoy CRM (customer relationship management) capabilities. They can develop enticing loyalty programs by integrating the rewards and loyalty capabilities of Blackbird. It helps to provide rewards to the large spenders and retain loyal customers.  Retailers can also benefit from a variety of marketing tools and indulge in sales campaigns by sending text messages.

Continue Reading

BUSINESS

State of Nevada Exempts Licensed Dispensaries And Cannabis Operators From Shut Down: 1933 Industries Inc (OTCMKTS:TGIFF) Continues To Operate As An Essential Business

Published

on

The state of Nevada has ordered shut down of all non-essential businesses. 1933 Industries Inc (OTCMKTS:TGIFF) will continue to operate as an essential business because the state of Nevada has exempted licensed dispensaries and cannabis operators from shut down.

Gives importance to safety

1933 Industries gives priority to the safety and health of its employees and partners while taking effective measures to prevent the spread of coronavirus. The company is committed to ensuring quality while maintaining solidarity with the communities in this difficult situation. All non-essential businesses are closed for the next 30-days in the state of Nevada.

1933 Industries will continue to operate its regular business amid the lockdown. It keeps all the manufacturing and cultivation operations open in Nevada to ensure the supply of premium cannabis concentrates.

Schedules second harvest for March-end

1933 Industries maintains the second harvest by the end of March 2020. It will take appropriate measures by closely monitoring the situation amid the COVID-19 pandemic. The company maintains sanitation and cleanliness in its operations while strictly following the stringent guidelines regarding safety. It is maintaining standard hygiene for all of its employees.

1933 Industries has restricted entry to visitors. It allows working of its employees in small groups to provide high-quality cannabis products and regularly monitors their health while strictly following the guidelines issued by the health authorities. The company also follows national, state, and local guidelines to protect its employees and prevent the spread of coronavirus.

1933 Industries conducts its business operations in Canada and the US. The company owns cannabis processing, extraction, cultivation, and manufacturing assets. It also holds leading cannabis brands. Portfolio of 1933 industries comprise CBD Infused Canna Hemp, AMA concentrates, AMA flower, Canna Fused, and Canna HempX. The company holds a 91% stake in the Alternative Medicine Association (AMA).

Completes new Las Vegas cultivation facility

1933 Industries has posted revenues of CAD 3.1 million in Q2 2020. It is a drop of 20% when compared to the previous quarter. The company has completed a new Las Vegas cultivation facility and commenced cultivation through its subsidiary – AMA. It also expanded its manufacturing and cultivation operations to California. The company also brought infrastructure projects in California and Nevada online while utilizing the resources.

Continue Reading

BUSINESS

Kalytera Therapeutics Inc (OTCMKTS:KALTF) Issues An Update On Acquisition Of Stero Biotechs, Ltd

Published

on

Kalytera Therapeutics Inc (OTCMKTS:KALTF) will take over Stero Biotechs, Ltd for $30 million. The company will issue its common shares worth $15 million to the shareholders of Stero. It will also issue additional common shares worth $15 million to Stero on successful completion of either phase 2a clinical trial that evaluates CBD for steroid-sparing in Chronic Urticaria and Crohn’s disease or on completing phase 2 clinical trial that evaluates CBD for steroid-sparing in any other indications. Kalytera will also issue common shares worth $5 million on commencing any phase 2a trial.

The acquisition is subject to receipt of third-party approvals

The takeover of Stero is subject to third-party and regulatory approvals. Kalytera also needs to get the approval of its shareholders and Stero’s shareholders. The share price should prevail above $0.05 CDN for this deal.

Developing CBD for co-administration with steroids

Israel based company – Stero is engaged in the development of CBD for co-administration with steroids. It helps to reduce the dosage of steroids and mitigate the safety issues in administering steroids. The company is currently conducting two phase 2a clinical trials that evaluate cannabidiol in steroid-sparing. It also has data from previous clinical trials that demonstrate the administration of steroids along with CBD considerably reduces the need for steroids. Therefore, it helps to reduce the use of steroids by up to 80%.

Extends maturity of the promissory note

Kalytera and the shareholders of its subsidiary – Talent Biotechs Ltd have agreed to extend the maturity date for the promissory note to May 15, 2020. The company expects to conclude the acquisition of Stero by May 15, 2020. Kalytera will become a leader in developing CBD pharmaceuticals with the takeover of Stero.

Chief Executive Officer and President of Kalytera, Robert Farrell, said the takeover of Stero will position the company as a leader in the development of CBD Pharmaceuticals. The US patent of Stero covers the use of cannabidiol for steroid-sparing in over 130 diseases for which steroid treatment is recommended. Therefore, the steroid-sparing program of Stero addresses large commercial opportunities. Therefore, Kalytera will have a robust CBD pharmaceutical development program, which will have great potential.

Continue Reading



Trending Stories